Refining Approaches to Overcome Challenges, Enhance Consistency, and Standardize Scoring and Reporting in HER2-Expressing Solid Tumors

Content Format:

Video

Credit Type:

ABIM MOC | ABPath MOC | AMA

Credits:

1.25
Best Practices in Testing and Treatment for Advanced ALK-Positive NSCLC and Overcoming Challenges to Implementation in Clinical Practice

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
Identifying and Mitigating Adverse Events Associated With ALK Inhibitors for Advanced ALK-Positive Non-Small-Cell Lung Cancer

Content Format:

PDF

Credit Type:

--

Credits:

--
Managing Advanced ALK-Positive Non-Small-Cell Lung Cancer: Considerations for Community Practitioners

Content Format:

PDF

Credit Type:

--

Credits:

--
Applying HER2 Testing Results to Treatment Decisions for Patients With Solid Tumors

Content Format:

Slideset

Credit Type:

--

Credits:

--
Addressing Key Questions: Expert Insights to Guide Pathologist-Informed Clinical Decisions in HER2-Expressing or Amplified Solid Tumors

Content Format:

Video

Credit Type:

ABIM MOC | ABPath MOC | AMA

Credits:

1.00
Applying HER2 Testing Results to Treatment Decisions for Patients With Solid Tumors

Content Format:

Slideset

Credit Type:

--

Credits:

--
Biomarker-Driven Lung Cancer Care: Application of New Standards and the Latest Research

Content Format:

Multimedia

Credit Type:

AMA

Credits:

1.75
Selecting Therapy for Less Common Driver Mutations in Advanced Lung Cancer: MET, RET, ALK, ROS, NTRK

Content Format:

Slideset Download

Credit Type:

--

Credits:

--
Using Biomarkers to Guide NSCLC Care: An Expert Discussion

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
Biomarker-Driven NSCLC Care: The Precision Medicine Model for Today and the Future

Content Format:

Multimedia

Credit Type:

AMA

Credits:

1.75
Selecting Therapy for Less Common Driver Mutations in Advanced Lung Cancer: ALK, ROS, RET, NTRK, MET

Content Format:

Slideset Download

Credit Type:

--

Credits:

--
NTRK Fusion in Lung Cancer and the Role of TRK Inhibitors

Content Format:

Multimedia

Credit Type:

AMA

Credits:

1.50
NTRK Fusion in Lung Cancer and the Role of TRK Inhibitors

Content Format:

Slideset Download

Credit Type:

--

Credits:

--
New Developments in NSCLC Targeted Therapy: Where We Are Heading in 2020

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
Experts Discuss Clinical Application of TRK Inhibitors and Tumor Agnostic NTRK Fusion Testing

Content Format:

Multimedia

Credit Type:

--

Credits:

--
The Biomarkers Oncologists Need to Know for Personalized Cancer Care in 2019

Content Format:

Multimedia

Credit Type:

AMA

Credits:

2.00
Clinical Data on TRK Inhibitors

Content Format:

Slideset Download

Credit Type:

--

Credits:

--
Realizing the Promise of Targeted Therapies in Cell Signaling: NTRK, ROS1, FGFR, RET

Content Format:

Slideset Download

Credit Type:

--

Credits:

--
Biomarker Summary: BRAF

Content Format:

PDF

Credit Type:

--

Credits:

--
Biomarker Summary: BRCA1/2

Content Format:

PDF

Credit Type:

--

Credits:

--
Biomarker Summary: Newly Approved Indications and Emerging Biomarkers

Content Format:

PDF

Credit Type:

--

Credits:

--
Biomarker Summary: FGFR

Content Format:

PDF

Credit Type:

--

Credits:

--
Biomarker Summary: HER2

Content Format:

PDF

Credit Type:

--

Credits:

--
Biomarker Summary: MSI/MMR

Content Format:

PDF

Credit Type:

--

Credits:

--
Biomarker Summary: PD-L1

Content Format:

PDF

Credit Type:

--

Credits:

--
Biomarker Summary: RET

Content Format:

PDF

Credit Type:

--

Credits:

--
Biomarker Summary: ROS1

Content Format:

PDF

Credit Type:

--

Credits:

--
Biomarker Summary: NTRK

Content Format:

PDF

Credit Type:

--

Credits:

--